Conference Summary

DENDREON
DNDN

press release date: May 8 , 2008
for quarter ending: March 31, 2008 (1st quarter)

I own this
Forward-looking statements

Overview: No analyst conference held. Financials in line with my expectations. Waiting for enough events in the Provenge trial to get the interim data.

Basic data:

Revenue was $31,000.

Net loss was $19.5 million.

EPS loss was $0.23 million.

$99.6 million in cash and equivalents.

Guidance:

None

Press Release Highlights:

"FDA agreed to amend the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) SPA, accelerating the expected timeline for final results from the study by approximately one year while maintaining comparable power to the previous SPA. In addition, the FDA reconfirmed that either a positive interim or final analysis of survival would support licensure and enable Dendreon to amend the Company's biologics license application for PROVENGE."

Neuvenge Phase I study showed it may be beneficial in breast, colorectal, and ovarian cancer.

Stock offering generated $46 million in cash, which should be enough to finish the IMPACT study.

Q&A:

No conference held

Dendreon Main Page
Dendreon corporate investor page
OpenIcon Analyst Conference Summaries Main Page

 

Search

More Analyst Conference Pages:

 
 ADBE
 AKAM
 ALTR
 AMAT
 AMD
 AMGN
 ANSV
 ATML
 BIIB
 CELG
 CHINA
 CSCO
 DELL
 DNA
 DNDN
 GILD
 GOOG
 HILL
 HPQ
 IBM
 INTC
 JNPR
 LLTC
 MCHP
 MOT
 MRVL
 MSFT
 MXIM
 NAPS
 NOVL
 NVDA
 ORCL
 ONXX
 RACK
 RHT
 STMP
 SUNW
 TXN
 XLNX
 YHOO

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2008 William P. Meyers